OS Therapies enters $10M convertible note financing with Leonite Fund; appoints Dr. Craig Eagle to board

OS Therapies Inc

Enters securities purchase agreement for up to $10M senior secured convertible note with Leonite Fund I, LP; first tranche of $1.6M expected July 2, 2026.
Note bears 9% interest, matures 9 months per tranche (max 24 months); conversion price $2.05/share; warrant to buy 1.75M shares at $2.85 through 2031.
Director Karim Galzahr resigns effective June 1, 2026; Dr. Craig Eagle appointed to fill vacancy, currently serves as Chief Medical Advisor.
Proceeds to fund clinical development, regulatory activities, and working capital.
Note secured by substantially all assets (excl. IP); includes negative covenants, anti-dilution adjustments, and 4.99% beneficial ownership limitation.

item 1.01 item 2.03 item 3.02 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.